Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma: Hodgkin
Lymphoma, Hodgkin Disease
Hodgkin Disease
Lymphoma

Interventions: Drug: Vincristine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Bleomycin
Drug: Etoposide
Radiation: Low-dose radiotherapy (RT)

First Posted Date: 2003-01-27

Last Posted Date: 2018-07-24

Lead Sponsor: Stanford University

Target Recruit Count: 76

Registration Number: NCT00026208

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Doxorubicin hydrochloride
Drug: Docetaxel
Radiation: Strontium chloride Sr 89
Drug: Estramustine phosphate sodium
Drug: Prednisone
Drug: Ketoconazole
Drug: Dexamethasone
Drug: Vinblastine

First Posted Date: 2003-01-27

Last Posted Date: 2016-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 265

Registration Number: NCT00024167

Locations: 🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸
University of Mississippi Cancer Clinic, Jackson, Mississippi, United States

and more 36 locations

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: AIDS-related Diffuse Large Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma

Interventions: Biological: rituximab
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: cyclophosphamide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 106

Registration Number: NCT00049036

Locations: 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2024-02-22

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1649

Registration Number: NCT00005584

Locations: 🇳🇱
Sint Antonius Ziekenhuis, Nieuwegein, Netherlands
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇳🇱
Leyenburg Ziekenhuis, 's-Gravenhage, Netherlands

and more 118 locations

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: dexamethasone
Drug: melphalan
Drug: prednisone

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-02

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 595

Registration Number: NCT00002678

Locations: 🇨🇦
Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦
William Osler Health Centre, Brampton, Ontario, Canada
🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada

and more 34 locations

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Phase 3

Completed

Conditions: Childhood Mixed Cellularity Classical Hodgkin Lymphoma
Stage I Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Stage II Childhood Hodgkin Lymphoma
Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Cytarabine
Biological: Filgrastim
Drug: Dexamethasone
Radiation: Involved-Field Radiation Therapy
Drug: Prednisone
Drug: Vincristine Sulfate Liposome

First Posted Date: 2003-01-27

Last Posted Date: 2017-04-12

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 1734

Registration Number: NCT00025259

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 172 locations

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: prednisone
Drug: thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2023-09-13

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 332

Registration Number: NCT00049673

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada

and more 15 locations

Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-15

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 475

Registration Number: NCT00004179

Locations: 🇳🇱
Amphia Ziekenhuis - locatie Molengracht, Breda, Netherlands
🇳🇱
Reinier de Graaf Group - Delft, Delft, Netherlands
🇿🇦
Sandton Oncology Centre, Johannesburg, South Africa

and more 256 locations

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Phase 3

Completed

Conditions: Stage 4S Neuroblastoma
Localized Unresectable Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
Localized Resectable Neuroblastoma

Interventions: Other: Clinical Observation
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Prednisone
Biological: Therapeutic Immune Globulin

First Posted Date: 2003-01-27

Last Posted Date: 2023-04-18

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 53

Registration Number: NCT00033293

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 101 locations

Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 79

Registration Number: NCT00020943

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States

and more 78 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy